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Abstract
Background: We are moving to second-wave analysis of genome-wide association studies (GWAS), characterized by
comprehensive bioinformatical and statistical evaluation of genetic associations. Existing biological knowledge is very
valuable for GWAS, which may help improve their detection power particularly for disease susceptibility loci of moderate
effect size. However, a challenging question is how to utilize available resources that are very heterogeneous to
quantitatively evaluate the statistic significances.
Methodology/Principal Findings:We present a novel knowledge-based weighting framework to boost power of the GWAS
and insightfully strengthen their explorative performance for follow-up replication and deep sequencing. Built upon diverse
integrated biological knowledge, this framework directly models both the prior functional information and the association
significances emerging from GWAS to optimally highlight single nucleotide polymorphisms (SNPs) for subsequent
replication. In the theoretical calculation and computer simulation, it shows great potential to achieve extra over 15% power
to identify an association signal of moderate strength or to use hundreds of whole-genome subjects fewer to approach
similar power. In a case study on late-onset Alzheimer disease (LOAD) for a proof of principle, it highlighted some genes,
which showed positive association with LOAD in previous independent studies, and two important LOAD related pathways.
These genes and pathways could be originally ignored due to involved SNPs only having moderate association significance.
Conclusions/Significance: With user-friendly implementation in an open-source Java package, this powerful framework will
provide an important complementary solution to identify more true susceptibility loci with modest or even small effect size
in current GWAS for complex diseases.
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Introduction
Genome-wide association studies (GWAS) have been widely
used in the past few years in the community of human genetics [1]
and have led to the identification of hundreds of loci affecting risk
for complex diseases [2]. By comprehensively examining genetic
association across the entire human genome, they could
attractively work without any priori hypotheses of the disease
genes. However, GWAS purely based on the statistical association
have also been noted for its limited power to discover predisposing
loci or genes with small or modest effect sizes [3,4]. According to a
large GWAS of seven common diseases [5], the associated single
nucleotide polymorphisms (SNPs) typically showed odds ratios
(ORs) of ,1.5. A very large sample size was required to detect
these SNPs. Many GWAS are actually underpowered to detect
these small or modest effects because of limited sample size [3].
Consequently, current GWAS of most complex traits only have
identified a small fraction of trait variance (5 to 10%), leaving
much of the heritability of these traits unexplained [6]. If we
presume that the unrevealed genetic variants have similar minor
allele frequencies and ORs as those identified for type 2 diabetes,
more than 800 genetic variants would be required to be able to
account for the 40% heritability of a complex disease [6].
Moreover, the existence of genetic heterogeneity of complex
diseases further challenges the performance of GWAS. Different
individuals may possess different disease risk alleles at different loci
in the same gene or in different genes. An individual predisposing
variant may well exhibit only weak or modest disease risk in a
sample even while it may show large risk in other samples.
Incorporation of the ever-increasing biological knowledge into
conventional statistic genetic analysis is becoming a promising
strategy to increase the detection power of genetic studies. It has
been found that SNPs do have some interesting features relevant
to disease risks. The most evident property is their gene features, if
available [7]. For instance, SNPs in non-synonymous coding
region are expected to have a higher chance to cause a disease
than SNPs within the intron [7]. Besides, some non-gene features
of SNPs may also provide clue of disease risk. According to recent
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studies, conservation [8], natural selection [9] and microRNA
binding [10,11] underlie human disease susceptibility. Intuitively,
SNPs within regions of strong conservation or strong natural
selection or microRNA binding sites are more likely to affect the
disease predisposition. Several approaches have been successfully
developed to select functionally important SNPs for experimental
design of genetic studies for human diseases [12,13,14], although
inevitably subject to potential knowledge bias.
Recent studies have also found that causative genes for the same
(or even phenotypically similar) diseases tend to distribute within
the same biological module [15]. The module can be a protein
complex [16], a pathway [17], a sub-network of protein-protein
interactions (PPIs) [18], or even other similar characteristics like
expression patterns [19]. In these shared biological modules, novel
underlying disease genes could be predicted from some known
disease genes. Based on this rationale, a number of computational
tools were made to infer disease genes such as ENDEAVOUR
[20], GeneWanderer [21] and CIPHER[22]. Taking advantage of
available knowledge as prior information, these methods can
greatly facilitate genetic mapping of disease genes that have
sufficient biological implications.
However, these knowledge-based prioritization methods did not
sufficiently utilize characteristics of GWAS. First, they cannot take
the GWAS p-values into account. Their prioritization is purely
base on the biological knowledge. A p-value cutoff is often set by
genetic investigators to select statistically interesting associations
for the knowledge-based prioritization analyses. It is, however,
difficult to determine an appropriate threshold for the selection. A
too stringent cutoff may run the risk of missing out many true
disease susceptibility loci (DSL) with only moderate p-values for
association while one too loose may introduce too many noises.
Second, the disease-gene prediction tools [20,21,23] were
originally developed for linkage analysis and often neglected
genomic features of SNPs. Currently, GWAS use much more
genetic markers than genome-wide linkage studies. Some markers
(SNPs) themselves have functional implication. For example, an
association signal of a SNP at the splicing intron sites of a
candidate gene should be given a higher priority than that of a
SNP at other intron sites of the same gene. Knowledge-based
prioritization analysis sufficiently considering all features of GWAS
may lead to a more powerful genetic mapping.
There have been several methods proposed to weight p-values
for association tests according to prior information. Holm [24]
first developed an idea of p-value weights. Benjamini and
Hochberg investigated the usage of weighting in a variety of
settings [25]. Genovese et al. used p-value weighting as a
frequentist method to add prior knowledge regarding test
hypotheses [26]. Roeder et al. developed a weight optimization
procedure to avoid the difficulty in selecting appropriate weights
for a particular analysis [27]. However, Roeder et al. (2007) had
two important limitations for GWAS. First, its statistical
exploration of optimal weights ignored the original prior
information essentially. Their optimization formula could only
ensure the maximization of the average power but could not
distinguish the strong-clue SNPs and the weak-clue ones.
Therefore, the SNPs in the strong-clue set might be negatively
weighted and were less likely to be associated with the disease in
question. This violated the original motivation to highlight SNPs
with strong functional implications and thus might raise difficulty
in interpreting the results. Second, their proposed grouping
strategy, although looked flexible, was very abstract. Typically, it
is difficult for users to construct proper SNP sets for a given disease
in practice because of the heterogeneousness of the diverse
information about diseases and genes.
This paper presents a novel bioinformatics and statistical
framework to systematically classify, weight, prioritize and
interpret association p-values from GWAS. It models both the
diverse biological knowledge and statistical association p-values
simultaneously to produce optimal weights for the prioritization.
This framework could boost power of current GWAS to identify
DSL with small or modest effect size. To test the performance
of the framework, we investigated its power by theoretical
calculations and empirical simulations, and examined its
effectiveness in connecting known associated genes between
two databases: the Online Mendelian Inheritance in Man
(OMIM) and the Genetic Association Databases (GAD). We
then applied this framework to a real case study to highlight
SNPs, genes and pathways about late-onset Alzheimer disease
(LOAD).
Materials and Methods
Data sources
We currently considered eight classes of biological resources in
our knowledge-based weighting framework. These diverse geno-
mic resources were integrated into two different datasets, (1) SNP
Genomic Features and (2) Gene Functions. These data are
updated periodically by our data-server program. More resources
will be added into the two datasets in the feature.
SNP Genomic Features dataset. The SNP information
dataset is made from four different resources. The major SNP data
were downloaded from the dbSNP database of NCBI (ftp://ftp.
ncbi.nih.gov/snp/organisms/human_9606/ASN1_flat/). The
software currently uses Build 130 (May 03, 2009), which
includes 17,804,036 Homo sapiens SNPs (7,344,853 within
genes). The second resource is the conservation score
information from the UCSC Genome Browser website (http://
hgdownload.cse.ucsc.edu/). The conservation scores were
generated based on sequence alignments of 16 vertebrate
genomes with the human genome. The third resource is the
positive selection score information of Phase 1 and Phase 2 SNPs
in the HapMap Project, downloaded from an analyzed dataset
(http://haplotter.uchicago.edu/selection/) [28]. The last one is
the human microRNA target gene binding site information from
Sanger’s miRBase (http://microrna.sanger.ac.uk/). We used
version 5.0, containing more than 879 thousand target binding
sites.
Gene Function dataset. The gene function dataset consist of
four kinds of gene information: (1) OMIM disease information, (2)
tissue specific-expression, (3) biological pathways, and (4) PPIs.
The OMIM’s [29] Morbid Map (MM) information (ftp://ftp.ncbi.
nih.gov/repository/OMIM/morbidmap), a compiled dataset of
human genetic disorders and responsible genes (containing 5,413
entries as of Feb. 22, 2010), was integrated to facilitate defining
seed candidate genes of given diseases. The tissue-specific
expression genes were download from an analyzed dataset of
mRNA expression arrays by Greco et al., where 1601 genes were
specifically express on 78 different human tissues [30]. Two
biological pathway databases were considered, KEGG (http://
www.genome.ad.jp/kegg/pathway.html) and BioCarta (http://
www.biocarta.com/). We collected and compiled 13,680 and
5,390 pathway-gene entries from the KEGG and BioCarta
databases, respectively (as of Dec. 11 2009). The PPI entries
were integrated from five databases: Human Protein Reference
Database (DPRD, http://www.hprd.org/) [31], Interologous
Interaction Database (I2D, http://ophid.utoronto.ca/i2d) [32],
Biomolecular Object Network Databank (BOND) [33], Molecular
INTeraction database (MINT, http://mint.bio.uniroma2.it/
Knowledge Weights P-Values
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mint/) [34] and General Repository Interaction Datasets
(BioGRID, http://www.thebiogrid.org/). The protein IDs in
these databases were mapped onto their genes symbols by our
program. The total number of unique pair-wise interactions
between genes was 100,268 (as of Dec. 11, 2009).
Construction of a bioinformatics and statistical
integration framework
We constructed a framework to integrate these biological
resources and weight SNPs’ association p-values from GWAS. The
kernel of integration framework is the weighting procedure as
shown in Figure 1. This procedure includes two main parts, A)
Bioinformatics Classification and B) Statistical Exploration. In the
part of Bioinformatics Classification, all SNPs are classified into
two distinct sets (the strong- and the weak-clue sets) based on
biological knowledge such as SNPs, genes, microRNA binding,
pathways and PPIs, integrated from various bioinformatics
databases. SNPs in the strong-clue set are assumed to have higher
disease risk than those in the weak-clue set. In the Statistical
Exploration part, a statistical approach is developed to produce
optimal weights for SNPs by modeling the risk set statuses (as prior
information) and association p-values of SNPs simultaneously. The
optimal weights here are defined as the weights which can 1)
maximize the average power of all tests on the whole genome
while controlling the family-wise error, and 2) highlight SNPs in
the strong-clue set.
Figure 1. Flow diagram showing the weighting procedure of the bioinformatics and statistical integration framework. In the figure,
Step A, B and C constitute the kernel part of the procedure. They run iteratively. In Step A, SNPs are classified into two distinct sets (a strong-clue set
and a weak-clue set) based on biological knowledge integrated from various bioinformatics databases. In Step B, a statistical exploration is conducted
to adjust p-values of SNPs by optimal weights that are in favor of the strong clues. In Step C, the top-n (say, Top-10) genes according to the weighted
p-values are selected to form a new set of seed candidate genes. The iteration stops when the weights in the current iteration are equal to the ones in
the last iteration. X1 and X2 are auxiliary steps. In Step X1, one can define a set of important seed candidate genes for the disease in question.
However, this step is optional. If there is no pre-defined seed candidate genes, the top-n (say, top-20) genes according to the original association p-
values are picked up to form a new set of seed candidate genes. In Step X2, biological knowledge of the highlighted SNPs can be specifically
retrieved to interpret the association significances under the framework.
doi:10.1371/journal.pone.0014480.g001
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The two parts run iteratively via an intermediate step, ‘‘Re-
defining seed candidate genes’’ (indicated as Step C in Figure 1).
The top-n (say, top-20) genes according to the newly weighted p-
values are chosen to form a new seed-gene set, which are used to
re-group the SNPs into two risk sets and then re-generate the
weights. The iteration does not stop until the weights converge
eventually. In addition, there are two auxiliary steps, (1) pre-
defining seed candidate genes, and (2) biological interpretation,
denoted as X1 and X2 in Figure 1 respectively. In Step X1, one
can define a set of initial seed-candidate genes, which are
probably confirmed by many previous independent genetic
studies and/or molecular functional studies for the disease in
question. However, this step is optional. If there are no pre-
defined seed candidate genes, the top-n genes according to the
original association p-values are selected to form a set of seed
genes. In Step X2, biological knowledge of the highlighted
SNPs can be specifically retrieved to interpret the association
significances. The framework has been implemented in an open-
source Java package named ‘‘A systematic biological Knowledge-
based mining system for Genome-wide Genetic studies’’ (KGG,
http://bioinfo.hku.hk/kggweb/). In addition, KGG can find
additional SNPs of the HapMap dataset in strong linkage
disequilibrium (LD) (say, r2.0.9) with the SNPs in the local
GWAS dataset. If the maximal risk score among the newly added
HapMap SNPs is larger than that of the local SNPs, the former
will be assigned to the local SNPs. This is a simple strategy to
access some missing functional SNPs using the typed tag-SNPs.
Preferably, one can perform weighting analysis for GWAS
association results which have been expanded by genotype
imputation.
Bioinformatics Classification. The seed candidate gene set
is used to introduce more candidate genes via an extension
protocol. The extended candidate gene set includes genes sharing
the same biological pathways with the seed genes, according to the
Kyoto Encyclopedia of Genes and Genomes (KEGG, http://
www.genome.ad.jp/kegg/pathway.html) and BioCarta (http://
www.biocarta.com/) pathway databases. In addition, the extended
set includes genes whose proteins interact with the proteins coded
by the seed genes. The underlying assumption is that genes
responsible for the same (or even phenotypically similar) diseases
are more likely to distribute within the same pathways or sub-
networks of PPIs [17,18].
The SNPs to be prioritized are then assigned putative disease
risk scores based on whether they are in the extended candidate
gene set and other genomic information of SNPs themselves via
a three-step scoring protocol. The protocol is detailed in Table
S1. First, SNPs are given preliminary risk scores according to
their gene features since SNPs of different gene features may
have different disease risk [7]. Second, these risk scores are
further adjusted according to three non-gene features, (1)
conservation scores, (2) positive selection scores, and (3)
microRNA binding status. SNPs with high conservation scores,
high positive selection scores, or within microRNAs’ target
binding sites are assumed to have higher disease risk [8,9,10,11].
Finally, SNPs belonging to candidate genes are given 3 more
points.
After the assignment of the risk scores, a risk score cutoff, four, is
used to divide SNPs into two distinct sets, the strong- and the
weak-clue sets. SNPs with risk scores equal to or over four belong
to the strong-clue set and the remainders are put into the weak-
clue set. According to the scoring protocol, once a SNP is within
the 2 kilo-base pairs (Kb) 59 or 500 base pairs (bp) 39 of a
candidate gene, it will have a score at least equal to four. That is,
this cutoff can ensure all SNPs of interested candidate genes to be
classified into the strong-clue set, which might be favorably
weighted. Meanwhile, the classification procedure implies that the
framework will never highlight SNPs far way from genes unless the
SNPs have at least two promising non-gene properties: high
conservation scores, high positive selection scores, or being within
microRNAs’ target binding sites.
Statistical Exploration. Assume there are mS and mW SNPs
in the strong- and weak-clue sets. Their test p-values in a genome-
wide association study are (p1, . . . ,pmS ) and (p1, . . . ,pmW )
respectively. These p-values correspond to standardized test
statistics (T1, . . . ,TmS ) and (T1, . . . ,TmW ). In the strong-clue set,
there are m0,S and m1,S SNPs following the null and alternative
hypotheses respectively. The proportion of null hypotheses is
p0,S~
m0,S
m0,Szm1,S
.The test statistics of null hypotheses are appro-
ximately under x2 distribution with 1 degree of freedom (d.f.). The
test statistics of alternative hypotheses are approximately x2(dS)
distributed with 1 d.f. and noncentrality parameter (NCP) dS. Here
we simply assume that all alternative hypotheses in the strong-clue
set are independent and under the identical x2(dS) distribution. In
the present study, the NCP is also called signal strength. Similarly,
in the weak-clue set, there are m0,W and m1,W SNPs following null
and alternative hypotheses respectively. The proportion of null
hypotheses is p0,W~
m0,W
m0,Wzm1,W
. The test statistics of alternative
hypotheses are approximately x2(dW ) distributed with 1 d.f. and
NCP dW.
The method of Storey and Tibshirani [35] after slight
modification was used to estimate the proportion of null hypotheses
in the strong and weak clue sets, p
_
0,S and p
_
0,W . The number of
alternative hypotheses in both sets are approximated as
m^1,S~½mS  (1{p_0,S) and m^1,W~½mW  (1{p_0,W ), respective-
ly. We then extended a method of Li and Yu (2009), the moment
estimate for truncated non-central chi-squared distribution, to infer
NCPsd^S and d^W in the two different SNP sets [36] (Please read the
Methods section of Supporting Information S1 for details).
Once the number and NCP of alternative hypotheses in both
SNP sets are obtained, we can start to explore the optimal weights.
Intuitively, the statistical exploration attempts to find proper
weights which maximize the number of significant SNPs while
controlling the overall false positive rate on the whole genome by
up-weighting SNPs following alternative hypotheses in strong-clue
set and down-weighting SNPs following alternative hypotheses in
the weak -clue set. Denote the weights for the strong- and weak-
clue sets by wS and wW respectively. Given a p-value rejection
threshold a, the power of a single weighted test in the strong-clue
set is g(dS,wS)~W(W
{1(
awS
2
){
ﬃﬃﬃﬃﬃ
dS
p
)zW(W{1(
awS
2
)z
ﬃﬃﬃﬃﬃ
dS
p
)
[27], whereW(x)~1{W(x) is the complement of the standard
normal cumulative distribution function. Analogously, the pow-
er of a single weighted test in the weak-clue set is g(dW ,wW )~
W(W{1(
awW
2
){
ﬃﬃﬃﬃﬃﬃﬃ
dW
p
)zW(W{1(
awW
2
)z
ﬃﬃﬃﬃﬃﬃﬃ
dW
p
). As we have
m1 =m1,S + m1,W alternatively hypotheses in total, the average
power in the whole genome is g~
1
m1
½m1,Sg(dS,wS)z
m1,Wg(dW ,wW ). An algorithm was developed to explore the
optimal wS and wW which can maximize the average power, g,
while 1) constraining m1,SwSzm1,WwW~m1,Szm1,W to control
the family-wise error and 2) constraining wS$wW to highlight
SNPs in the strong-clue set by favorable weights. The weights are
used to adjust association p-values of SNPs; a weighted p-value is
equal to the original one divided by the weight. These weighted p-
values are valid for multiple-comparison methods like the standard
Bonferroni and false discovery rate (FDR) corrections [37]. Details
Knowledge Weights P-Values
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of the Statistical Exploration are described in the Methods section
of Supporting Information S1. From the frequentist viewpoint, a
weighted p-value may be no longer a standard p-value at least for
a single test. As it is an adjusted p-value given a prior weight, to
some extent, it can be regarded as ‘‘the Bayesian posterior p-
value’’. If we borrow similar idea in Storey (2003), it may be more
sensible to name a weighted p-value as ‘‘q-value’’ which was
originally introduced to interpret the positive false discovery rate
[38].
Computer simulations
In genetic association studies, the association p-value of
alternative hypotheses is usually affected by two important factors,
effect size (i.e. genetic relative risk) of DSL and sample size. Thus,
we used simple computer simulation (which assumes the DSL have
been assigned into the strong-clue set) to basically look into how
they affect the performance of our weighting approach. The
LOAD was supposed as our target disease in the simulation. Three
genes (GAPDHS, PRNP and ACE) were randomly selected from a
LOAD gene set proposed by Bertram et al. as susceptibility genes
of the simulated disease [4]. Each gene is assumed to have one
LOAD predisposing SNP. The three SNPs (rs11882238 and
rs12625444 and rs4351) have different minor allele frequencies
(0.0750, 0.2167 and 0.4167). We simulated genotypes and
phenotypes to investigate the power and false positives of our
weighting approaches. Detailed methods of the simulation are
described in the Methods section of Supporting Information S1.
Candidate gene extension and testing
Although it is impossible to completely validate the candidate-
gene extension protocol (the fist step of the weighting procedure as
indicated in Figure 1), a conceptual verification by available
datasets is still feasible. In the present study, we collected genes as
seed candidates for each disease in the OMIM database. Then we
expanded the seed candidate gene set by our protocol for each
disease. In the expanded gene set, we counted genes which had
positive association for the same disease reported by previous
studies in the GAD. The coverage percentage for a disease was
defined as the proportion of these genes positively reported in the
GAD among the expanded candidate gene set. In the OMIM’s
MM file, out of 5,183 MM entries, 3,897 entries with the ‘‘(3)’’ tag
(indicating that at least one mutation in the particular gene was
causative to the disorder) were selected for the validation. In the
GAD on March 10, 2009, there were 11,571 (out of 39,910) items
with positive association annotation. Diseases having less than
three seed candidate genes were excluded. Consequently, 108
unique diseases were left eventually. A p-value was calculated by
the cumulative hyper-geometric distribution to evaluate the
significance of the coverage:
p~1{
Xm{1
i~0
CiMC
n{i
N{M
CnN
:
where N is the number of all known human genes and M is the
number of genes positively reported to be associated with the given
disease in the GAD. The n is the number of expanded genes based
on the seed candidate genes for a disease and m is the number of
genes in the expanded candidate gene set and positively reported
in GAD as well.
Application to a real LOAD dataset
The LOAD dataset. We downloaded a LOAD dataset from
the TGEN database (http://www.tgen.org/research/index.
cfm?pageid=1065, Translational Genomics Research Institute;
TGEN). It contained 961 histopathologically verified Caucasian
LOAD cases and 550 age-matched controls, which were collected
from three cohorts, ‘‘neuropathological discovery cohort’’,
‘‘neuropathological replication cohort’’ and ‘‘clinical replication
cohort’’. These subjects were at least 65 years old at the time of
their death or last clinical assessment. The Affymetrix 500K
GeneChip (Affymetrix, Santa Clara, CA) was used to survey
502,267 SNPs in each subject. Genotypes were called by SNiPer-
HD [39] and BRLMM (Affymetrix) software. Additional
description of the dataset can be found in Reiman et al. (2007).
Knowledge-based weighting analysis. After producing
allelic association p-values using PLINK [40], we used KGG to
conduct the knowledge-based weighting analysis to highlight SNPs
and genes which might be promising for replication. We forced
KGG to choose the top 20 genes according to SNPs p-values as seed
genes. The seed gene set was expended by including genes having
two-level PPI and sharing the same pathways with the seed genes.
SNPs in the dataset were classified into the strong- and weak-clue
sets according to their gene features, the conservation (default
threshold 0.8) and selection scores (default threshold 2.0 according
to the HapMapCEU population), miRNA binding site information,
and the expanded candidate gene set. The weighting procedure was
allowed to iterate until the optimal weights converged. In the
iteration, the top-20 genes according to the weighted association p-
values were picked up to form a new set of seed genes. Pathways
containing over 300 or less than 2 genes were excluded. The FDR
method of Benjamini and Hochberg (1995) was used for multiple-
testing correction with an error rate 5%.
Significance of pathway enrichment. The significance of
pathway enrichment is also measured by a p-value according to
the cumulative hyper-geometric distribution.
Results
Theoretical power gain and power loss
Figure S6 shows the theoretically increased power (or power
gain) and decreased power (or power loss) for detecting a true
alternative hypothesis in the two sets (Detailed methods of the
simulation are described in the Methods section of Supporting
Information S1). The power gain is related to the signal strengths
or NCPs of the alternative hypotheses in both sets. As shown in
Figure S6(a), a large power gain (over 10%) can occur only when
the signal strength is approximately within the region [4,6]. This
result implies that our weighting method is more effective for
alternative hypothesis with midsize signal strength. Therefore, in
the implementation of the weighting method, we excluded the p-
values which have been already statistically significant. On the
contrary, the power loss, nonetheless, is generally very small
regardless of the signal strengths. As shown in Figure S6(b), the
largest power loss for an alternative hypothesis in the weak-clue set
is only 0.4%, which corresponds to the power gain 17% in the
strong-clue set. The large difference between the amount of power
gain and power loss implies the worthwhile trying of our weighting
method.
Computer simulation results
The Figure S3, Tables S3 and S4 show that the power gain of
the weighting approach varies with the relative genetic risks. When
the genetic risk leads to midsize signal strength, the power gain can
be over 15% for SNPs in the strong-clue set. However, when the
effect size is too small or too large, the power gain becomes small,
compared with the original statistical test. When the susceptible
SNP is in the weak-clue set, our weighting framework almost has
Knowledge Weights P-Values
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14480
the same power as the original test (only shown in Tables S3 and
S4). Figure 2 shows the relationship between power gain and
sample size. The pattern is quite similar to that in Figure S3.
When the sample size corresponds to moderate signal strength, the
power gain can be very large (again over 15%). If the sample size is
very large, the original method has already had high power (say,
over 90%) to identify the SNPs and so there is little room for any
improvement. In addition, Figure 2 also indicates that the
weighting approach may save hundreds of whole-genome subjects
to achieve an acceptable power in practice, say 80%, compared
with original statistical methods.
All these results observed in the simulation coincide with the
theoretical calculation above except that the weighted method
detects slightly more false positive discoveries (Shown in the Tables
S3 and S4). This cannot be explained by our statistical model
because the family-wise error has already been controlled
theoretically. The most likely reason is the dependence of SNPs
due to linkage disequilibrium between neighborhood SNPs, which
is difficult to be modeled theoretically. At any rate, the inflated
false positive rate is quite small and may merely result in minor loss
of cost compared to the benefit from the power gain. For example,
The Monte Calor mean of false positive number is 0.78( = 1.92–
Figure 2. Comparison of power between the weighted and non-weighted basic allelic association tests in the simulated dataset
when sample size varies. Plots a), b) and c) show the power identifying rs11882238, rs12625444 and rs4351 under the dominant model,
respectively. Meanwhile, Plots d), e) and f) represent the power under multiplicative mode for the three SNPs. All of the three SNPs are assumed to be
in the strong-clue set. The sample size increases from 2000 to 6400 by 400 with equal number of cases and controls. On the plots 1K denotes 1000
subjects. The curves are smoothed by the natural cubic spline method. The maximal power difference between these curves is labeled by a dashed
vertical line on each plot. The dashed horizontal line indicates the saved whole-genome sample size by our knowledge-based weight approach for a
given power compared with the original statistical test.
doi:10.1371/journal.pone.0014480.g002
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1.14) at genetic risk 1.55 (in the Tables S3) among all tested 28370
SNPs [2.75E-5( = 0.78/28370) per test] while the power to identify
rs11882238 can be 17.1% (= 59.9%242.8%) higher than the
original test. Therefore, it may be acceptable to tolerate slightly
more false associations to gain one or several true associations,
similar to the reason of the application of FDR approach [41].
Effectiveness of candidate gene extension by OMIM and
GAD
Figure S4 and Table S5 show how many genes in the GAD can
be derived from the OMIM genes through our candidate gene
extension protocol. In the histogram of the coverage for the 73
diseases (Figure S4), 68(93.2%) diseases have the coverage $ 50%.
It is 80% or so for many common complex diseases such as
Diabetes Mellitus, Obesity, Alzheimer’s disease (AD) and Parkin-
son’s disease. These results imply the effectiveness of our weighting
framework for many human complex diseases. Once the OMIM
genes are utilized as seed candidate genes, most promising genes in
the GAD will be deduced and SNPs these genes might be
highlighted by our weighting procedure.
Knowledge-based analysis in a LOAD dataset: a case
study
We applied this weighting framework to prioritize and interpret
associations in a published real LOAD dataset for a genome-wide
case-control study [42]. This dataset included 307448 SNPs
passing quality control criteria. Each SNP had an allelic
association p-value, which was generated by Plink [40]. The
genomic inflation factor for the 307448 p-values (based on median
chi-squared) was 1.07125, indicating a slight inflation of moderate
association significance in the dataset. Figure S1 shows the Q-Q
plot of the p-values. We defined these p-values as the ‘‘original p-
values’’ and inputted them into KGG for the knowledge-based
weighting analysis. According to the original p-values, there was
only one significantly associated SNP, rs4420638 (p= 3.6E-36),
Benjamini and Hochberg (1995) test with FDR 0.05.
SNPs were marked with risk scores and separated into the
strong- and weak-clue sets based on the integrated knowledge in
our dataset. Two optimal weights for the strong- and weak-clue
sets, 7.77 and 0.001, were ultimately obtained by the default
settings on KGG. In the strong-clue set there were 1194 (2.78%)
SNPs were assigned the high weights and 8088 (3.03%) SNPs in
the weak-clue set were given the low weight. There were 308 SNPs
with the weighted p-values # 5.0E-4 (listed in the Table S6).
We did literature survey for genes containing weighted p-values
(or q-values) #5.0E-4 at their highlighted SNPs, listed in the Table
S6. Because few SNPs overlapped across datasets of various studies,
we limited survey to involved genes, which were positively reported
to be associated with LOAD at least once in GAD, Alzforum
database (http://www.alzforum.org/res/com/gen/alzgene/default.
asp), and in the NCBI PubMed. Fourteen genes (except for the
extremely significant gene APOC1, a gene 5 kb away from APOE)
were suggested as susceptibility genes by at least one previous
independent study (Detailed in Table S2) among 188 genes with up-
weighted SNPs p-values #5.0E-4. Among the 14 genes, two genes,
IL1RN and GAB2, have more than 3 independent studies suggesting
their susceptibility to LOAD. IL1RN encodes proteins inhibiting the
activities of interleukin 1, alpha (IL1A) and interleukin 1, beta (IL1B),
which is related to immune and inflammatory responses. There are
growing evidences supporting that inflammatory processes most
certainly play an important role in the pathogenesis of AD [43]. In
the annotation analysis on KGG, we found this gene had a 2-level
indirect PPI with 11 important candidate genes (Figure 3 (a)). GAB2
is a member of the growth factor receptor–bound protein 2(GRB2)-
associated binding protein (GAB) gene family. GRB2 has been
reported to bind tau, amyloid-b precursor protein (APP), and
PSEN1 and PSEN2. These interactions have been advised to regulate
Figure 3. Three 2-level PPI sub-network enriched by IL1RN, GAB2 and important candidate genes. This figure is plotted by our tool KGG.
Each node denotes a gene labeled by ‘‘Gene Symbol’’. The edge indicates a PPI between proteins encoded by two genes. The red and green nodes
denote the tested genes with significant SNPs and important candidate genes respectively. Here the ‘‘2-level’’ means that the minimal length from a
tested gene to an important candidate gene is 2 (edges). There are intermediate genes (in gray on the plot) between the tested gene and important
candidate genes, which have PPI with the both.
doi:10.1371/journal.pone.0014480.g003
Knowledge Weights P-Values
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14480
signal transduction and to be involved in the pathogenesis of
AD [44,45]. In our PPI dataset, it has indirect PPIs with
12 important candidate genes including the PPIs GAB2<
GRB2<APP (Figure 3 (b)). We also tried similar literature survey
for the original association p-values. There are 294 SNPs (belong-
ing to 112 different genes) whose original association p-values
are # 5.0E-4. In the GAD, Alzforum database, and PubMed,
there was only one gene, COL11A1, among the 112 genes supported
by only one genetic association study of LOAD [46], except for
the extremely significant gene APOC1. The weighting method
largely enriched previously reported genes to be 4.47:1 ( = 15/
188:2:112).
Apart from the association consistent with previously findings at
the gene level, there are also two interesting pathways enriched by
both the genes with highlighted SNP and some very important
candidate genes of AD (Figure S5). The first one is the KEGG AD
pathway. Seven genes (COX7B2, SNCA, GRIN2A, SDHA, PPP3CA,
CACNA1C and CACNA1D) with the highlighted SNPs in the Table
S6 and six important candidate genes clustered within this
pathway (shown in the Figure S2). The other interesting pathway,
although not so obvious as the AD pathway, is the Calcium
signaling pathway. Twelve genes (EGFR, GNA14, PDE1A, EDNRA,
GNAL, TRPC1, ADCY2, GRIN2A, RYR2, CACNA1C, PPP3CA and
CACNA1D) with highlighted SNPs and one important candidate
gene (NOS3) are enriched in this pathway. Given the very small p-
values, there is every reason to suspect that certain unraveled
functional implications of the LOAD underlay these significant
enrichments. Actually, association between the Calcium signaling
pathway and the AD has been proposed by many molecular
genetic and genetic epidemiological studies [47,48], which
supports the intraneuronal calcium dysregulation hypothesis of
AD [49].
While these genes with previous supporting and enriched
pathways provide a ‘‘proof of principle’’, other genes with
highlighted SNPs, although their function for LOAD has not
been well studied, are also of interests. For instance, suggestive
association significance (according to the weighted p-value) occurs
at the missense polymorphism (rs7817227) of C8orf80. These SNPs
and genes should also be given higher priority in the following-up
replications.
Discussion
We have presented a novel bioinformatics and statistical
framework to prioritize SNPs of GWAS. Unlike previous
bioinformatics disease-loci prediction approaches, this weighting
method in our framework directly modeled both biological
knowledge and statistic association significances emerging from
GWAS to produce optimal weights for the prioritization. It could
properly up-regulate the moderate p-values for SNPs but with
strong functional clues. This framework has a potential to largely
improve the power of current GWAS to identify more DSL,
particularly those with modest effect size. In addition, the
integrated biological context also helps on interpreting the
observed association and thus speculating the genetic and
pathogenic mechanisms of a disease.
We conducted a series of investigations to examine the
effectiveness of this framework. In the theoretical calculation
and computer simulation, it had great potential to achieve extra
over 15% power to identify an association signal of midsize
strength. According to the empirical simulation results (Figure 2),
the weighting approach might save hundreds of whole-genome
samples to get the same acceptable power, say 80%, compared
to the original association test. In a validation test, its candidate
gene extension protocol had a very good performance to cover
previously reported genes for the most common diseases in
GAD. In the application to a LOAD dataset for the purpose of a
proof of principle, it highlighted some genes that were suggested
as susceptibility genes of LOAD by previous independent
genetic studies and two important AD related pathways. Taken
together, this framework provided a worthwhile alternative to
strengthen the explorative performance of the GWAS. It may be
particularly useful for the prioritization of SNPs for follow-up
replications at the first stage of the multistage GWAS design
[50] and for deep sequencing studies. The whole weighting
procedure and other assistant functions like tracking and
visualization of the biological knowledge have been built in a
user-friendly open-source tool named KGG (http://bioinfo.hku.
hk/kggweb/).
In the literature survey, we included all genes for which at least
one association study (either family or case-control studies)
concluded the positive association. Admittedly, given the fact that
conflicting findings in genetic studies of complex diseases occur
commonly regardless of study design, there are also negative
reports for the genes we showed in the Table S2, which are not
listed in the present paper. However, we assumed that both
negative and positive association studies in various populations
might be correct with the underlying reason of genetic
heterogeneity in different populations, and possible gene-gene
and gene-environment interactions [51,52]. Also due to this
reason, an individual GWAS in a specific population cannot
present association signals at all possible susceptibility genes. That
may be the reason why even the 12 genes proposed by meta-
analysis [4] were not highlighted ultimately in our case study as
well. Probably, this dataset do not contain association signal at
these genes. In addition, we also compare our results with one of
the latest GWAS published in Nature Genetics [53]. In the Table S2
of this paper, showing association p-values,1.0E-3, 32 genes were
highlighted by our weighting procedure. In their table there were
219 genes having registry in our LOAD GWAS dataset which
includes 15300 genes in total. Our weighting procedure highlight-
ed 555 genes in total. The probability of highlighting the 32 genes
and more by chance is very small, 1.64E-11 (cumulative hyper-
geometric distribution).
It should be noted that we did not use any well-known
candidate genes of LOAD as the initial seed genes to train the
weighting framework. Otherwise, it may be subjected to the
criticism of circular logic because these important candidate genes
tend to be studied more by previous candidate-gene studies and
are more likely to be selected in our literature survey. However,
the important candidate genes could be used to introduce other
novel but functionally related genes based-on this general
foundation. Statistically, the important candidate genes are
regarded as prior information. Taking into account the prior
information, our method will re-evaluate the association in the
local dataset, which is a Bayes-like idea. Therefore, in real analyses
of GWAS, we suggest using some important candidate genes (if
available) as initial seed genes to generate hypothesis for
replication. If the important candidate genes have suggestively
significant SNP p-values, it may well be highlighted by our
weighting procedure and need to be replicated using new data.
However, our weighting procedure may also spotlight other
interesting genes which have functional correlation with the
important candidate genes and suggestively significant association
p-values.
Our integrated dataset has obvious partiality for SNPs within
genes at present. Because most available biological resources are
biased toward genes, SNPs pertaining to known genes could have
Knowledge Weights P-Values
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much more relevant prior information. Consequently, the
resulting weights may be more effective for associated SNPs
belonging or close to known genes. Actually, there is a trend of
gene-centricity among available GWAS findings. According to a
recent survey of 118 GWAS articles, 68% of reported SNPs with
disease association lie within 60 Kb of a RefSeq gene [54]. This
gene-centricity trend may imply that the susceptibility loci within
and around genes are really dominant although not all. Therefore,
methods that focus more on gene regions could still be productive
regardless of their intrinsic bias. Moreover, for complex diseases,
functionally validating association hits far from gene region
remains to be an intractable challenge up to now. Setting out
from the relatively easier points is a feasible strategy. In any case,
we have begun to partly address this issue by considering three
kinds of non-gene information, conservation score, selection score,
and miRNA binding. More information will be added in the
future. In fact, knowledge bias is a common and intrinsic limitation
of all knowledge-based analysis methods e.g., [12,20,21,22,55,56].
As the limitation seemed not to prohibit the success of these
methods in applications, it is unlikely that it will significantly
confine the application of our framework.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0014480.s001 (0.04 MB
DOC)
Figure S2
Found at: doi:10.1371/journal.pone.0014480.s002 (0.09 MB
DOC)
Figure S3
Found at: doi:10.1371/journal.pone.0014480.s003 (0.05 MB
DOC)
Figure S4
Found at: doi:10.1371/journal.pone.0014480.s004 (0.03 MB
DOC)
Figure S5
Found at: doi:10.1371/journal.pone.0014480.s005 (0.27 MB
DOC)
Figure S6
Found at: doi:10.1371/journal.pone.0014480.s006 (0.09 MB
DOC)
Supporting Information S1
Found at: doi:10.1371/journal.pone.0014480.s007 (0.27 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0014480.s008 (0.04 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0014480.s009 (0.11 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0014480.s010 (0.11 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0014480.s011 (0.11 MB
DOC)
Table S5
Found at: doi:10.1371/journal.pone.0014480.s012 (0.24 MB
DOC)
Table S6
Found at: doi:10.1371/journal.pone.0014480.s013 (0.75 MB
DOC)
Author Contributions
Conceived and designed the experiments: MXL PCS YQS. Performed the
experiments: MXL. Analyzed the data: MXL. Wrote the paper: MXL
PCS SC.
References
1. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, et al. (2008)
Genome-wide association studies for complex traits: consensus, uncertainty and
challenges. Nat Rev Genet 9: 356–369.
2. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into
the genetics of common disease. J Clin Invest 118: 1590–1605.
3. Altshuler D, Daly M (2007) Guilt beyond a reasonable doubt. Nat Genet 39:
813–815.
4. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic
meta-analyses of Alzheimer disease genetic association studies: the AlzGene
database. Nat Genet 39: 17–23.
5. Consortium WTCC (2007) Genome-wide association study of 14,000 cases of
seven common diseases and 3,000 shared controls. Nature 447: 661–678.
6. Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation
and its contribution to complex traits. Nat Rev Genet 10: 241–251.
7. Tabor HK, Risch NJ, Myers RM (2002) Candidate-gene approaches for studying
complex genetic traits: practical considerations. Nat Rev Genet 3: 391–397.
8. Kulkarni V, Errami M, Barber R, Garner HR (2008) Exhaustive prediction of
disease susceptibility to coding base changes in the human genome. BMC
Bioinformatics 9(Suppl 9): S3.
9. Blekhman R, Man O, Herrmann L, Boyko AR, Indap A, et al. (2008) Natural
selection on genes that underlie human disease susceptibility. Curr Biol 18:
883–889.
10. Lu M, Zhang Q, Deng M, Miao J, Guo Y, et al. (2008) An analysis of human
microRNA and disease associations. PLoS ONE 3: e3420.
11. Sethupathy P, Collins FS (2008) MicroRNA target site polymorphisms and
human disease. Trends Genet 24: 489–497.
12. Hemminger BM, Saelim B, Sullivan PF (2006) TAMAL: an integrated approach
to choosing SNPs for genetic studies of human complex traits. Bioinformatics 22:
626–627.
13. Reumers J, Maurer-Stroh S, Schymkowitz J, Rousseau F (2006) SNPeffect v2.0:
a new step in investigating the molecular phenotypic effects of human non-
synonymous SNPs. Bioinformatics 22: 2183–2185.
14. Wang PL, Dai MH, Xuan WJ, McEachin RC, Jackson AU, et al. (2006) SNP
Function Portal: a web database for exploring the function implication of SNP
alleles. Bioinformatics 22: E523–E529.
15. Oti M, Brunner HG (2007) The modular nature of genetic diseases. Clin Genet
71: 1–11.
16. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, et al. (2007) A
human phenome-interactome network of protein complexes implicated in
genetic disorders. Nat Biotechnol 25: 309–316.
17. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic
landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
18. Lim J, Hao T, Shaw C, Patel AJ, Szabo G, et al. (2006) A protein-protein
interaction network for human inherited ataxias and disorders of Purkinje cell
degeneration. Cell 125: 801–814.
19. Franke L, van Bakel H, Fokkens L, de Jong ED, Egmont-Petersen M, et al.
(2006) Reconstruction of a functional human gene network, with an appli-
cation for prioritizing positional candidate genes. Am J Hum Genet 78:
1011–1025.
20. Aerts S, Lambrechts D, Maity S, Van Loo P, Coessens B, et al. (2006) Gene
prioritization through genomic data fusion. Nat Biotechnol 24: 537–544.
21. Kohler S, Bauer S, Horn D, Robinson PN (2008) Walking the interactome for
prioritization of candidate disease genes. Am J Hum Genet 82: 949–958.
22. Wu X, Jiang R, Zhang MQ, Li S (2008) Network-based global inference of
human disease genes. Mol Syst Biol 4: 189.
23. Adie EA, Adams RR, Evans KL, Porteous DJ, Pickard BS (2006) SUSPECTS:
enabling fast and effective prioritization of positional candidates. Bioinformatics
22: 773–774.
24. Holm S (1979) A Simple Sequentially Rejective Multiple Test Procedure.
Scandinavian Journal of Statistics 6: 65–70.
25. Benjamini Y, Hochberg Y (1997) Multiple hypotheses testing with weights.
Scandinavian Journal of Statistics 24: 407–418.
26. Genovese CR, Roeder K, Wasserman L (2006) False discovery control with p-
value weighting. Biometrika 93: 509–524.
Knowledge Weights P-Values
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14480
27. Roeder K, Devlin B, Wasserman L (2007) Improving power in genome-wide
association studies: weights tip the scale. Genet Epidemiol 31: 741–747.
28. Voight BF, Kudaravalli S, Wen X, Pritchard JK (2006) A map of recent positive
selection in the human genome. PLoS Biol 4: e72.
29. McKusick VA (2007) Mendelian Inheritance in Man and its online version,
OMIM. Am J Hum Genet 80: 588–604.
30. Greco D, Somervuo P, Di Lieto A, Raitila T, Nitsch L, et al. (2008) Physiology,
pathology and relatedness of human tissues from gene expression meta-analysis.
PLoS ONE 3: e1880.
31. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, et al.
(2003) Development of human protein reference database as an initial platform
for approaching systems biology in humans. Genome Res 13: 2363–2371.
32. Brown KR, Jurisica I (2007) Unequal evolutionary conservation of human
protein interactions in interologous networks. Genome Biol 8: R95.
33. Bader GD, Betel D, Hogue CW (2003) BIND: the Biomolecular Interaction
Network Database. Nucleic Acids Res 31: 248–250.
34. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, et al.
(2007) MINT: the Molecular INTeraction database. Nucleic Acids Res 35:
D572–574.
35. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies.
Proc Natl Acad Sci U S A 100: 9440–9445.
36. Li QZ, Yu K (2009) Inference of non-centrality parameter of a truncated non-
central chi-squared distribution. Journal of Statistical Planning and Inference
139: 2431–2444.
37. Wasserman L, Roeder K (2006) Weighted hypothesis testing. Available: http://
arxivorg/abs/mathST/0604172.
38. Storey JD (2003) The positive false discovery rate: A Bayesian interpretation and
the q-value. The Annals of Statistics 31: 2013–2035.
39. Hua J, Craig DW, Brun M, Webster J, Zismann V, et al. (2007) SNiPer-HD:
improved genotype calling accuracy by an expectation-maximization algorithm
for high-density SNP arrays. Bioinformatics 23: 57–63.
40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
41. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a
Practical and Powerful Approach to Multiple Testing. Journal of the Royal
Statistical Society Series B-Methodological 57: 289–300.
42. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, et al. (2007) GAB2
alleles modify Alzheimer’s risk in APOE epsilon4 carriers. Neuron 54: 713–720.
43. Seripa D, Matera MG, Dal Forno G, Gravina C, Masullo C, et al. (2005)
Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically
and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 26:
455–464.
44. Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, et al. (2008)
Phosphorylation regulates tau interactions with Src homology 3 domains of
phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family
kinases. J Biol Chem 283: 18177–18186.
45. Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, et al. (2007) Amyloid
precursor protein and Presenilin1 interact with the adaptor GRB2 and modulate
ERK 1,2 signaling. J Biol Chem 282: 13833–13844.
46. Taguchi K, Yamagata HD, Zhong W, Kamino K, Akatsu H, et al. (2005)
Identification of hippocampus-related candidate genes for Alzheimer’s disease.
Ann Neurol 57: 585–588.
47. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, et al. (2008)
Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of
InsP3 receptor channel gating. Neuron 58: 871–883.
48. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, et al. (2008)
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and
Alzheimer’s disease risk. Cell 133: 1149–1161.
49. LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in
Alzheimer’s disease. Nat Rev Neurosci 3: 862–872.
50. Pahl R, Schafer H, Muller HH (2009) Optimal multistage designs—a general
framework for efficient genome-wide association studies. Biostatistics 10:
297–309.
51. Risch N, Merikangas K (1996) The future of genetic studies of complex human
diseases. Science 273: 1516–1517.
52. Schjeide BM, Hooli B, Parkinson M, Hogan MF, DiVito J, et al. (2009) GAB2 as
an Alzheimer disease susceptibility gene: follow-up of genomewide association
results. Arch Neurol 66: 250–254.
53. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009)
Genome-wide association study identifies variants at CLU and PICALM
associated with Alzheimer’s disease. Nat Genet 41: 1088–1093.
54. Johnson AD, O’Donnell CJ (2009) An open access database of genome-wide
association results. BMC Med Genet 10: 6.
55. Reumers J, Maurer-Stroh S, Schymkowitz J, Rousseau F (2006) SNPeffect v2.0:
a new step in investigating the molecular phenotypic effects of human non-
synonymous SNPs. Bioinformatics 22: 2183–2185.
56. Wang P, Dai M, Xuan W, McEachin RC, Jackson AU, et al. (2006) SNP
Function Portal: a web database for exploring the function implication of SNP
alleles. Bioinformatics 22: e523–529.
Knowledge Weights P-Values
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e14480
